Literature DB >> 30375263

The Shiraz Breast Cancer Registry (SBCR): study design and primary reports.

Abdolrasoul Talei1, Sedigheh Tahmasebi1, Majid Akrami1, Vahid Zangouri2, Abbas Rezaianzadeh1, Peyman Arasteh1, Tannaz Eghbali1, Sara Hosseini1.   

Abstract

AIM: This is a description of the largest breast cancer (BC) registry in Iran, termed the Shiraz Breast Cancer Registry (SBCR).
METHODS: Data on baseline and clinical characteristics, socioeconomic status, imaging, physical examination, histopathology, treatment and prognosis have been recorded for each individual.
RESULTS: Overall, 5937 were included in the report. Mean age of first presentation was 49.05 ± 11.69 years. Mean tumor size was 2.78 ± 1.76 cm. Most patients had stage 2 (46.9%) and 3 (25.5%) BCs, respectively. Most common type of BC was invasive ductal carcinoma (83.3%), followed by medullary carcinoma (3.8%). Overall, 12.9% were triple negative (HER2-, ER- and PR-).
CONCLUSION: The study provides an overview on the status of BC's in Iran and a wide opportunity for future studies.

Entities:  

Keywords:  Iran; breast cancer; epidemiology; protocol; registry

Mesh:

Year:  2018        PMID: 30375263     DOI: 10.2217/pme-2018-0047

Source DB:  PubMed          Journal:  Per Med        ISSN: 1741-0541            Impact factor:   2.512


  2 in total

1.  Chronological changes and trend of breast cancer clinics and pathology among Iranian women during 22 years from the largest breast cancer registry in Iran.

Authors:  Sedigheh Tahmasebi; Mahsa Tajali; Majid Akrami; Peyman Arasteh; Vahid Zangouri; Aida Salehi Nobandegani; Seyed Morteza Hosseini; Afsoon Safari; Abdolrasoul Talei
Journal:  World J Surg Oncol       Date:  2019-12-04       Impact factor: 2.754

2.  Intraoperative radiation therapy for early stage breast cancer.

Authors:  Vahid Zangouri; Hamid Nasrollahi; Ali Taheri; Majid Akrami; Peyman Arasteh; Seyed Hassan Hamedi; Masoumeh Ghoddusi Johari; Nazanin Karimaghaee; Aliye Ranjbar; Mohammad Yasin Karami; Sedigheh Tahmasebi; Ahmad Mosalaei; Abdolrasoul Talei
Journal:  BMC Surg       Date:  2022-01-26       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.